InsiderTrades

Versant Venture Capital VI, L.P.

SEC CIK 1687880 · EDGAR

Buying vs selling by month open-market trades, last 26 months, all 3 companies
BoughtSold

Companies

TickerCompanyTitleHoldingBoughtSoldTradesFirstLast
LENZLENZ Therapeutics, Inc.10% 1.18M — $15.97M 42025-08-152025-09-18
GLUEMonte Rosa Therapeutics, Inc.10% 1.59M — $8.89M 42024-09-202024-10-28
TPSTTempest Therapeutics, Inc.10% 597.9K — $966.8K 12024-08-082024-08-08

Most active insiders at LENZ, 12 months

#InsiderTitleBoughtSold
1 Versant Vantage II GP-GP, LLC10% —$10.35M
2 Olsson ShawnChief Commercial Off —$261.0K
3 Schimmelpennink Evert B.Pres, CEO, Sec, Dir $251.4K—
4 MCCOLLUM JAMES WDir $239.3K—
5 Chevallard Daniel R.CFO $114.3K—
6 George Jeffrey P.Dir $49.9K—

Versant Venture Capital VI, L.P. made no open-market trades at LENZ in the last 12 months.

Transactions 9

Type
Reset
X Filed Traded Ticker Company Insider Title Type Price Qty Owned ΔOwn Value
M 2025-09-22 2025-09-18 LENZ LENZ Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% S - Sale $42.23 -90.7K 1.18M -7% -$3.83M
MI 2025-09-22 2025-09-18 LENZ LENZ Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% S - Sale $42.23 -44.6K 856.3K -5% -$1.89M
MI 2025-08-19 2025-08-15+ LENZ LENZ Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% S - Sale $39.33 -85.0K 962.9K -8% -$3.34M
M 2025-08-19 2025-08-15+ LENZ LENZ Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% S - Sale $39.34 -175.7K 1.43M -11% -$6.91M
MI 2024-10-30 2024-10-28+ GLUE Monte Rosa Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% S - Sale $9.44 -157.9K 1.59M -9% -$1.49M
2024-10-30 2024-10-28 GLUE Monte Rosa Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% J - Other $0.00 -1.02M 4.08M -20% $0
MI 2024-10-30 2024-10-28 GLUE Monte Rosa Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% J - Other $0.00 -366.6K 1.64M -18% $0
2024-09-24 2024-09-20 GLUE Monte Rosa Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% S - Sale $6.53 -1.13M 5.10M -18% -$7.40M
M 2024-08-12 2024-08-08+ TPST Tempest Therapeutics, Inc. Versant Venture Capital VI, L.P. 10% S - Sale $1.23 -788.0K 597.9K -57% -$966.8K

Purchase Sale Sale after option exercise All abbreviations